重庆医学
重慶醫學
중경의학
CHONGQING MEDICAL JOURNAL
2014年
12期
1436-1438
,共3页
杨帆%谭保平%何柳平%王红%吴昊
楊帆%譚保平%何柳平%王紅%吳昊
양범%담보평%하류평%왕홍%오호
经皮冠状动脉介入治疗%血小板聚集%CD41+CD62P+%氯吡格雷
經皮冠狀動脈介入治療%血小闆聚集%CD41+CD62P+%氯吡格雷
경피관상동맥개입치료%혈소판취집%CD41+CD62P+%록필격뢰
percutaneous coronary intervention%platelet aggregation%CD41+CD62P+%clopidogrel
目的:观察经皮冠状动脉介入治疗(PCI)术患者氯吡格雷停用后血小板聚集率及血小板CD41+ CD62P+表达的变化。方法对52例已服用氯吡格雷12个月但即将停药的PCI患者,比较氯吡格雷治疗前(T0)、治疗后1周(T1),停药前1周(T2)、停药后1周(T3)及停药后1个月(T4)血小板聚集率和血小板CD41+CD62P+阳性率。结果与T0比较,T1血小板聚集率及CD41+CD62P+表达均显著下降,差异有统计学意义(P<0.05);T2仍维持较低水平;T3血小板聚集率及CD41+ CD62P+表达升高,T4血小板聚集率及CD41+ CD62P+恢复至 T0水平,T0、T1、T2、T3、T4各时间点血小板聚集率分别为(44.20±18.36)%、(25.38±12.10)%、(23.74±8.15)%、(51.79±10.55)%、(45.97±16.42)%,血小板CD41+ CD62P+阳性率分别为(12.96±11.48)%、(3.93±3.33)%、(4.72±3.14)%、(13.90±10.38)%、(10.84±8.13)%。结论 PCI术后已服用氯吡格雷12个月者,停用氯吡格雷后1周时血小板聚集率、血小板CD41+CD62P+阳性率轻度增加,在停药后1个月时逐渐恢复至停药前水平。
目的:觀察經皮冠狀動脈介入治療(PCI)術患者氯吡格雷停用後血小闆聚集率及血小闆CD41+ CD62P+錶達的變化。方法對52例已服用氯吡格雷12箇月但即將停藥的PCI患者,比較氯吡格雷治療前(T0)、治療後1週(T1),停藥前1週(T2)、停藥後1週(T3)及停藥後1箇月(T4)血小闆聚集率和血小闆CD41+CD62P+暘性率。結果與T0比較,T1血小闆聚集率及CD41+CD62P+錶達均顯著下降,差異有統計學意義(P<0.05);T2仍維持較低水平;T3血小闆聚集率及CD41+ CD62P+錶達升高,T4血小闆聚集率及CD41+ CD62P+恢複至 T0水平,T0、T1、T2、T3、T4各時間點血小闆聚集率分彆為(44.20±18.36)%、(25.38±12.10)%、(23.74±8.15)%、(51.79±10.55)%、(45.97±16.42)%,血小闆CD41+ CD62P+暘性率分彆為(12.96±11.48)%、(3.93±3.33)%、(4.72±3.14)%、(13.90±10.38)%、(10.84±8.13)%。結論 PCI術後已服用氯吡格雷12箇月者,停用氯吡格雷後1週時血小闆聚集率、血小闆CD41+CD62P+暘性率輕度增加,在停藥後1箇月時逐漸恢複至停藥前水平。
목적:관찰경피관상동맥개입치료(PCI)술환자록필격뢰정용후혈소판취집솔급혈소판CD41+ CD62P+표체적변화。방법대52례이복용록필격뢰12개월단즉장정약적PCI환자,비교록필격뢰치료전(T0)、치료후1주(T1),정약전1주(T2)、정약후1주(T3)급정약후1개월(T4)혈소판취집솔화혈소판CD41+CD62P+양성솔。결과여T0비교,T1혈소판취집솔급CD41+CD62P+표체균현저하강,차이유통계학의의(P<0.05);T2잉유지교저수평;T3혈소판취집솔급CD41+ CD62P+표체승고,T4혈소판취집솔급CD41+ CD62P+회복지 T0수평,T0、T1、T2、T3、T4각시간점혈소판취집솔분별위(44.20±18.36)%、(25.38±12.10)%、(23.74±8.15)%、(51.79±10.55)%、(45.97±16.42)%,혈소판CD41+ CD62P+양성솔분별위(12.96±11.48)%、(3.93±3.33)%、(4.72±3.14)%、(13.90±10.38)%、(10.84±8.13)%。결론 PCI술후이복용록필격뢰12개월자,정용록필격뢰후1주시혈소판취집솔、혈소판CD41+CD62P+양성솔경도증가,재정약후1개월시축점회복지정약전수평。
Objective To investigate the changes of platelet aggregation rate and platelet surface CD 41+CD62P+ expression af-ter clopidogrel discontinuation in the patients with percutaneous coronary interventions (PCI)) .Methods The platelet aggregation rates and platelet surface CD41+CD62P+ in 52 PCI patients with oral clopidogrel for near 12 months and discontinuation soon were measured before clopidogrel therapy(T0 ) ,in 1 week after clopidogrel therapy(T1 ) ,1 week before clopidogrel discontinuation(T2 ) , 1 week(T3 ) and 1 month after clopidogrel discontinuation (T4 ) .Results Compared with T0 ,the platelet aggregation rate and the expression of platelet CD41+CD62P+ at T1 were significantly decreased ,the difference showing statistical significance (P<0 .05) , which at T2 maintained the lower levels ;which at T3 were increased ,which at T4 were recovered to those at T0 .The platelet aggre-gation rates at various time points were (44 .20 ± 18 .36)% ,(25 .38 ± 12 .10)% ,(23 .74 ± 8 .15)% ,(51 .79 ± 10 .55)% and(45 .97 ± 16 .42)% respectively ,and the positive rates of CD41+ CD62P+ were(12 .96 ± 11 .48)% ,(3 .93 ± 3 .33)% ,(4 .72 ± 3 .14)% , (13 .90 ± 10 .38)% and(10 .84 ± 8 .13)% ,respectively .Conclusion In the patients treated with 12-month clopidogrel after PCI ,the platelet aggregation rate and the CD41+CD62P+ positive rate are mildly increased at 1 week after clopidogrel discontinuation and gradually returned to the level before discontinuation at 1 month after clopidogrel discontinuation .